Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies

New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme

VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ:OPTH) (CSE:OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages. The products are available to qualified, authorized clinical research organizations.

Microdosing refers to taking low, sub-perceptual doses of a psychedelic on a repeated schedule. Common regimens include the Fadiman protocol (one day on, two days off) and the Stamets protocol (four days on, three days off), which build in rest days to limit tolerance.